"@Dorry_Segev I saw the AstraZeneca sponsored story, and in it they cited the trial of Evushield 2 in the footnotes. Are there any trials for new post-postive-test mABs aka the old bebtelovimab? I had a great a/b response to vaxes, so not sure Evushield 2 is as useful?"